Previous 10 | Next 10 |
Image source: The Motley Fool. Castle Biosciences Inc (NASDAQ: CSTL) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading
Castle Biosciences (NASDAQ: CSTL ): Q1 GAAP EPS of $0.03 beats by $0.18 . More news on: Castle Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Q1 2020 DecisionDx-Melanoma test report volume increased 42% compared to Q1 2019 Q1 2020 revenues of $17.4 million, compared to $8.7 million in Q1 2019, an increase of 100% Operating cash flow for Q1 2020 was $(0.3) million Cash and cash equivalents as of March 31, 2020, totaled $98.7 mi...
Published Recently in Current Medical Research and Opinion Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a clinical utility model for its cu...
Published Recently in the Journal of the American Academy of Dermatology Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of development and...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the first quarter ended March 31, 2020, after the close of market on Mond...
The following slide deck was published by Castle Biosciences, Inc. in conjunction with this Read more ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 19th Annua...
Published Recently in the Journal of the American Academy of Dermatology Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a systematic review a...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 44 th Annual Growth Conference on Tuesday, Aug. 13, 2024, at ...
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...